The Answer to Cancer is Research
Yhim has a partnership with the University of Chicago Cancer Research Foundation to fund studies that will aid in the ultimate goal of finding a cure for cancer. Each year we dedicate financial resources for unique and crosscutting work that deepens human understanding of cancer through insights that can be applied to a variety of treatments and applications. Your commitment to Yhim allows us to continue these important studies and research.
Yhim announced funding for the work of a cancer researcher at the University of Chicago named Bryan Dickinson. His lab utilizes chemistry, biology, and physics to revolutionize the way the molecular level of cancer is viewed. The specific work focused on enzymes and proteins in cancer acquisition with the hope of finding a way to disrupt their progress by erasing them.
This work is ongoing and its details and progress will be updated in the coming months.
Focus: Disruption of Cancer-Causing Protein-Protein Interactions. Study: Researchers focused on the protein-protein interaction hubs that are critical for cancer acquisition, maintenance, and immune evasion. While there are some therapeutic approaches that disrupt these interactions, they are currently limited to a small number of specific kind of protein-protein interactions. This study worked to expand that progress. Result: The project leveraged biosensors created in the laboratory to develop strategies that would evolve molecules that disrupt cancer-causing protein-protein interactions which had not previously been “druggable”.
Focus: Chemotherapy-Induced Peripheral Neuropathy Study: This two-year study concentrated on a condition, peripheral neuropathy, that can result from taking the chemotherapy drug Vincristine. Peripheral neuropathy is nerve damage in the hands and feet that can result in weakness, numbness, and pain. Peripheral neuropathy can reduce the quality of life of cancer patients and there are no FDA-approved drugs available to prevent or treat this side effect. Result: Researchers created preclinical models to study the underlying mechanisms responsible for peripheral neuropathy caused by Vincristine. Having accurate models that reflect what occurs within patients would be considered a significant breakthrough since no patient-derived cell models previously existed. The hope is that these patient-derived cell models will allow for the screening of drugs to prevent or treat chemotherapy-induced peripheral neuropathy.
Focus: Bone Marrow Disorders Study: Researchers concentrated on a diverse group of bone marrow disorders known as Myelodysplastic Syndromes (MDS). MDS occur when the bone marrow does not produce enough healthy blood cells. Result: Insights from this study may result in the ability to repair bone marrow abnormalities resulting from these genetic defects. This could provide the foundation for the treatment of and prevention strategies for MDS and leukemia.
Focus: Prostrate Cancer Study: Researchers studied the evolution of solid tumors by comparing genetic changes over time and space to identify genetic biomarkers. The biomarkers were then used in the prognosis and prediction of response to therapy. Result: This study resulted in the use of Magnetic Resonance Imaging (MRI) to personalize the treatment of localized prostate cancer.
mission & vision
Yhim's mission is to generate greater awareness and funds to further much needed cancer research.
Join the cause
Yhim is currently seeking volunteers, interns and board members. For more information, please email us at email@example.com.
Thank you for your interest and support of Yhim. We have big plans for its future…think blue in June as you now think pink in February and May.
Yhim will look to celebrate life by raising funds and building awareness year-round, focusing efforts around Fathers' Day weekend. Although Yhim was inspired by the passing of one father on Fathers' Day, cancer does not discriminate nor will our efforts. Funds raised support cutting edge research that will impact us ALL.
Yhim was inspired by one special father, Joseph S. Jerbich. Like so many before him, in the Spring of 2000, Joseph was diagnosed with cancer which eventually took him on Fathers' Day 2002. To mark the tenth anniversary of Joseph's passing his son Michael, with the help of loving family and friends, established Yhim in honor of his father's memory.
Yhim will look to celebrate life by raising funds and building awareness year-round, focusing efforts around Fathers' Day weekend. Although yhim was inspired by the passing of one father on Fathers' Day, Cancer does not discriminate and nor will our efforts. Funds raised support cutting edge research that will impact us ALL.
With your help, Yhim will strive to eliminate cancer through partnerships with world-class health institutes and organizations. Yhim is a not-for-profit organization with proceeds going to cancer research.